XM does not provide services to residents of the United States of America.
A
A

Amgen

Technical Summary

IndicatorValueTrend
IndicatorValueTrend
IndicatorValueTrend
IndicatorS3S2S1PR1R2R3

News

Wall Street awaits Amgen weight-loss drug data expected to move shares

ANALYSIS-Wall Street awaits Amgen weight-loss drug data expected to move shares Amgen's MariTide aims for quicker weight loss, fewer doses than GLP-1 drugs Analysts expect MariTide to show at least 20% weight loss Concerns over side effects, including nausea and bone density issues By Deena Beasley Nov 21 (Reuters) - Upcoming data from a mid-stage study of Amgen's AMGN.O experimental weight-loss drug MariTide will shed light on how well it might measure up against the popular GLP-1 drugs sold by
A

Lilly pill cuts genetic form of cholesterol nearly 86% in study

Lilly pill cuts genetic form of cholesterol nearly 86% in study By Julie Steenhuysen CHICAGO, Nov 18 (Reuters) - The highest dose of an experimental pill developed by Eli Lilly LLY.N dramatically lowered an inherited form of high cholesterol in a mid-stage trial, according to data presented at a medical meeting on Monday. The drug, muvalaplin, reduced levels of lipoprotein(a), or Lp(a), by 70% using a traditional blood test and by nearly 86% based on a more specific test developed by the company
A
N

Wall St indexes mixed; Nvidia earnings, Fed policy in focus

US STOCKS-Wall St indexes mixed; Nvidia earnings, Fed policy in focus For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window. Nvidia falls after report Blackwell chips overheating Tesla jumps after report Trump team's could ease rules CVS Health gains on new board appointments in Glenview deal Indexes: Dow down 0.08%, S&P 500 up 0.10%, Nasdaq up 0.24% Updated at 09:43 a.m.
A
A
G
N
U
U
L

Drugmakers extend declines after Trump picks RFK Jr to lead top US health agency

BUZZ-Drugmakers extend declines after Trump picks RFK Jr to lead top US health agency Updates ** Shares of vaccine makers extend declines after President-elect Donald Trump selected Robert F. Kennedy Jr to lead the Department of Health and Human Services, the United States' top health agency ** U.S.-listed shares of BioNTech 22UAy.DE , BNTX.O down ~5% to $98.41, Moderna MRNA.O falls 5.20% to $37.50, Novavax NVAX.O down ~3% at $7, while Pfizer PFE.N down 4.05% at $24.97 ** Kennedy has frequently
A
J
P

U.S. STOCKS Talen Energy, Biogen, Ovintiv

BUZZ-U.S. STOCKS ON THE MOVE-Talen Energy, Biogen, Ovintiv Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes were subdued on Thursday after monthly producer prices rose as expected, with investors awaiting Fed Chair Jerome Powell's comments later in the day for clues on the outlook for interest rates.
A
A
B
C
N
W
U
U
A
H

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.